Cargando…
Perspectives of Immune Therapy in Coronavirus Disease 2019
The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211516/ https://www.ncbi.nlm.nih.gov/pubmed/32383371 http://dx.doi.org/10.3346/jkms.2020.35.e176 |
_version_ | 1783531463824637952 |
---|---|
author | Gasparyan, Armen Yuri Misra, Durga Prasanna Yessirkepov, Marlen Zimba, Olena |
author_facet | Gasparyan, Armen Yuri Misra, Durga Prasanna Yessirkepov, Marlen Zimba, Olena |
author_sort | Gasparyan, Armen Yuri |
collection | PubMed |
description | The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV-2 and neutralize its aggressive actions on multiple organ systems. Protective cross-reactivity of antibodies against measles and other known viral infections has been postulated, primarily as a result of the initial observations of asymptomatic and mild COVID-19 in children. Uncontrolled case series have demonstrated virus-neutralizing effect of convalescent plasma, supporting its efficiency at early stages of contracting SARS-CoV-2. Given the variability of the virus structure, the utility of convalescent plasma is limited to the geographic area of its preparation, and for a short period of time. Intravenous immunoglobulin may also be protective in view of its nonspecific antiviral and immunomodulatory effects. Finally, human monoclonal antibodies may interact with some SARS-CoV-2 proteins, inhibiting the virus-receptor interaction and prevent tissue injury. The improved understanding of the host antiviral responses may help develop safe and effective immunotherapeutic strategies against COVID-19 in the foreseeable future. |
format | Online Article Text |
id | pubmed-7211516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-72115162020-05-14 Perspectives of Immune Therapy in Coronavirus Disease 2019 Gasparyan, Armen Yuri Misra, Durga Prasanna Yessirkepov, Marlen Zimba, Olena J Korean Med Sci Review Article The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV-2 and neutralize its aggressive actions on multiple organ systems. Protective cross-reactivity of antibodies against measles and other known viral infections has been postulated, primarily as a result of the initial observations of asymptomatic and mild COVID-19 in children. Uncontrolled case series have demonstrated virus-neutralizing effect of convalescent plasma, supporting its efficiency at early stages of contracting SARS-CoV-2. Given the variability of the virus structure, the utility of convalescent plasma is limited to the geographic area of its preparation, and for a short period of time. Intravenous immunoglobulin may also be protective in view of its nonspecific antiviral and immunomodulatory effects. Finally, human monoclonal antibodies may interact with some SARS-CoV-2 proteins, inhibiting the virus-receptor interaction and prevent tissue injury. The improved understanding of the host antiviral responses may help develop safe and effective immunotherapeutic strategies against COVID-19 in the foreseeable future. The Korean Academy of Medical Sciences 2020-05-07 /pmc/articles/PMC7211516/ /pubmed/32383371 http://dx.doi.org/10.3346/jkms.2020.35.e176 Text en © 2020 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Gasparyan, Armen Yuri Misra, Durga Prasanna Yessirkepov, Marlen Zimba, Olena Perspectives of Immune Therapy in Coronavirus Disease 2019 |
title | Perspectives of Immune Therapy in Coronavirus Disease 2019 |
title_full | Perspectives of Immune Therapy in Coronavirus Disease 2019 |
title_fullStr | Perspectives of Immune Therapy in Coronavirus Disease 2019 |
title_full_unstemmed | Perspectives of Immune Therapy in Coronavirus Disease 2019 |
title_short | Perspectives of Immune Therapy in Coronavirus Disease 2019 |
title_sort | perspectives of immune therapy in coronavirus disease 2019 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211516/ https://www.ncbi.nlm.nih.gov/pubmed/32383371 http://dx.doi.org/10.3346/jkms.2020.35.e176 |
work_keys_str_mv | AT gasparyanarmenyuri perspectivesofimmunetherapyincoronavirusdisease2019 AT misradurgaprasanna perspectivesofimmunetherapyincoronavirusdisease2019 AT yessirkepovmarlen perspectivesofimmunetherapyincoronavirusdisease2019 AT zimbaolena perspectivesofimmunetherapyincoronavirusdisease2019 |